The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index; 64 of the 121 sources its claims cite were checked for support.
Abstract
GLP-1 receptor agonist (GLP-1RA) medications have transformed the treatment of type 2 diabetes (T2D) and obesity, with robust evidence for cardiovascular and renal benefits. Nevertheless, GLP-1RA therapy is associated with a pattern of adverse events affecting their safety and tolerability. Here, we delineate mechanisms potentially leading to adverse responses to GLP-1RAs, describe the impact of side effects on treatment persistence, discuss potential mitigation strategies, and identify areas requiring further studies. Concerns that GLP-1RAs raise the risk for acute pancreatitis and pancreatic cancer have been dispelled by long-term clinical trials. However, GLP-1RAs may confer an increased risk for thyroid cancer. Sight-threatening eye complications resulting from rapid reductions in glycemia may be avoided by retinal screening and ophthalmologic treatment before GLP-1RA initiation. The slowing of gastric emptying with GLP-1RA treatment increases the propensity for retained gastric contents, which could increase the risk of aspiration during upper gastrointestinal endoscopy or general anesthesia. These risks may, however, be elevated in individuals with long-standing T2D even in the absence of GLP-1RA treatment. Improved pharmacovigilance and a more standardized, quantitative assessment of adverse events in clinical trials, particularly in the assessment of gastrointestinal symptoms, would facilitate definition of the benefit-risk relationship for individual medications.
Overview
CoChat Summary
## TL;DR
This is a narrative review of adverse effects associated with GLP-1 receptor agonists (and tirzepatide), emphasizing gastrointestinal tolerability, thyroid and eye safety, and risks in specific populations. The paper argues that several feared harms (notably pancreatitis and pancreatic cancer) have been largely dispelled by longer-term trials, while GI side effects, retained gastric contents, and possible thyroid/ocular risks remain clinically important.
## Key findings
- In a systematic review of 39 randomized controlled trials in people without diabetes, GLP-1RAs increased risk of nausea, vomiting, diarrhea, and constipation versus placebo; for newer therapies, nausea risk versus placebo was semaglutide RR 2.95 (95% CI 2.61–3.32), tirzepatide RR 2.90 (95% CI 2–4.19), and orforglipron RR 4.77 (95% CI 2.02–11.31).
- In another systematic review of 38 phase III/IV placebo-controlled trials in T2D, nausea occurred in 19.3% with active treatment versus 6.5% with placebo, and vomiting in 7.6% versus 2% with placebo; 6.5% of GLP-1RA users discontinued due to adverse events versus 3.6% on placebo.
- GLP-1RAs were associated with increased retained gastric contents: one study reported 56% in GLP-1RA users versus 19% in non-users; three systematic reviews found increased odds of premature endoscopy termination from retained gastric contents (OR 4.5, 5.6, and 13.9), but no review found an increased risk of aspiration pneumonia.
- The review states that concerns about acute pancreatitis and pancreatic cancer have been “dispelled” by long-term trials, but that GLP-1RAs may confer an increased risk for thyroid cancer and that retinopathy complications can occur with rapid glycemic improvement, especially in people with pre-existing advanced retinopathy.
## Methods
- Narrative review of GLP-1 receptor agonist safety, covering GI, psychiatric, ocular, thyroid, biliary/pancreatic, and population-specific adverse effects.
- Synthesizes evidence from systematic reviews, randomized controlled trials, cohort studies, case-control studies, and pharmacovigilance reports, with examples drawn from T2D, obesity, cirrhosis, CKD, older adults, pregnancy, and younger individuals.
- Main analysis is qualitative synthesis of published studies, reporting relative risks, odds ratios, hazard ratios, and event rates where available; no new primary data collection is described.
## Limitations
- The paper itself notes that surprisingly little research has comprehensively assessed even common GI adverse events, and that adverse-event documentation is suboptimal, making differences between compounds/preparations hard to appreciate.
- It also states that many safety signals rely on pharmacovigilance databases and observational studies, which are prone to reporting bias and confounding; this is explicitly stated in the paper.
- Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of underlying studies; several sections explicitly say larger, prospective, or dedicated studies are needed to confirm associations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
50 Valid · 3 Not valid · 34 Not checked · 11 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“a substantial proportion (>50%) of the participants did not report any GI adverse events”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Disputedcites [21] Aroda VR et al High-dose semaglutide (up to 16 mg) in people with type 2 diabetes and overweight or obesity: a randomized, placebo-controlled, phase 2 trial Diabetes Care 2025 48 6 905 913 10.2337/dc24-2425 40279144 PMC12094194 sourceExperimental — accuracy not yet measured
The Results > Safety table reports gastrointestinal disorders in 28 of 60, 41 of 60, 44 of 62, and 20 of 59 participants across the four groups. That totals 133 of 241 participants (55%) reporting a GI adverse event, leaving fewer than 50% without one across the trial. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“most human medullary thyroid carcinomas and hyperplastic C cells express GLP-1R (75, 77) (Figure 2).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > Thyroid carcinomas
What the sources say
- Supportedcites [75] Gier B et al Glucagon like peptide-1 receptor expression in the human thyroid gland J Clin Endocrinol Metab 2012 97 1 121 131 10.1210/jc.2011-2407 22031513 PMC3412261 source
The Results (Table 2; page unavailable) show GLP-1R immunoreactivity in 11 of 12 medullary thyroid carcinomas and all nine C-cell hyperplasia specimens. The Discussion also describes expression as common in both, while noting that the proportion of positive cells varies within lesions. (LLM, conf=0.93)
- Disputedcites [77] Pach D et al Glucagon-like peptide-1 receptor imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2]-exendin-4 for the diagnosis of recurrence or dissemination of medullary thyroid cancer: a preliminary report Int J Endocrinol 2013 2013 384508 10.1155/2013/384508 23606839 PMC3626320 sourceExperimental — accuracy not yet measured
The Discussion reports GLP-1R expression in 28% of medullary thyroid carcinomas examined, contrary to the claim that most express it. It also says many calcitonin-positive C cells were GLP-1R-negative; the copy does not establish expression in most hyperplastic C cells. No page number is provided in our copy. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Supportedcites [16] Kang YM et al Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes Obes Metab 2025 27 7 3736 3746 10.1111/dom.16398 40212008 PMC12146062 source
This source is cited for the randomized-clinical-trial portion of the sentence, not the separately cited real-world portion. The Discussion explicitly refers to treatment discontinuation due to GI adverse events, and the Results (Safety and tolerability outcomes; page unavailable) report that 6.5% of participants receiving incretin mimetics discontinued because of adverse events. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [17] Bettge K et al Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials Diabetes Obes Metab 2017 19 336 347 10.1111/dom.12824 27860132 source
- Not checked — no full text of the sourcecites [18] Weeda ER et al Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: a meta-analysis Int J Clin Pract 2021 75 9 e14060 10.1111/ijcp.14060 33527605 source
- Partly supportedcites [19] Wilke T et al Non-persistence and non-adherence of patients with type 2 diabetes mellitus in therapy with GLP-1 receptor agonists: a retrospective analysis Diabetes Ther 2016 7 1 105 124 10.1007/s13300-015-0149-4 26695499 PMC4801815 sourceExperimental — accuracy not yet measured
For the real-world-practice portion attributed to this paper, the Discussion (Study Objectives and Main Results; page unavailable) reports that 5.0% of UK patients and 12.3% of German patients received no second GLP-1 prescription, and suggests this may be due to common gastrointestinal adverse events. It does not establish that those events caused the discontinuations. The randomized-trial portion is cited to other sources, not this paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > Abstract
What the sources say
- Not checked — no full text of the sourcecites [8] Thorens B Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1 Proc Natl Acad Sci U S A 1992 89 18 8641 8645 10.1073/pnas.89.18.8641 1326760 PMC49976 source
- Not checked — no full text of the sourcecites [9] Wei Y Mojsov S Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences FEBS Lett 1995 358 3 219 224 10.1016/0014-5793(94)01430-9 7843404 source
- Not checked — no full text of the sourcecites [10] Alvarez E et al Expression of the glucagon-like peptide-1 receptor gene in rat brain J Neurochem 1996 66 3 920 927 10.1046/j.1471-4159.1996.66030920.x 8769850 source
- Not checked — no full text of the sourcecites [11] Pyke C Knudsen LB The glucagon-like peptide-1 receptor--or not? Endocrinology 2013 154 1 4 8 10.1210/en.2012-2124 23267050 source
- Supportedcites [12] McLean BA et al Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation Endocr Rev 2021 42 2 101 132 10.1210/endrev/bnaa032 33320179 PMC7958144 source
The paper reports GLP-1R expression in pancreatic islet β-cells (Concluding remarks for GLP-1R expression and function in the pancreas, p. 20), throughout the CNS (Where does brain GLP-1 originate from?, p. 21), and across the GI tract (GLP-1R expression in the gastrointestinal tract, p. 40). It describes expression in only a subset of renal blood vessels (p. 37) and fewer than 1% of cells in the human retinal ganglion cell layer (p. 48), consistent with the claim's less-prominent qualification. (LLM, conf=0.86)
- Supportedcites [13] Hebsgaard JB et al Glucagon-like peptide-1 receptor expression in the human eye Diabetes Obes Metab 2018 20 9 2304 2308 10.1111/dom.13339 29707863 PMC6099507 source
The Results (GLP-1R expression in normal human eyes) found receptor-positive cells in less than 1% of ganglion cell layer cells and weaker staining in the monkey renal cortex. This supports the cited paper’s contribution to the statement that expression in the eyes, and to a lesser extent the kidney, is limited; it does not establish the sentence’s separate comparison with brain expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“6.5% of those using a GLP-1RA discontinued it due to adverse events versus 3.6% of those on placebo (16)”
§ The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications > GI side effects
What the sources say
- Partly supportedcites [16] Kang YM et al Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes Obes Metab 2025 27 7 3736 3746 10.1111/dom.16398 40212008 PMC12146062 sourceExperimental — accuracy not yet measured
The Results (Safety and tolerability outcomes, ‘Treatment discontinuation’) report 6.5% discontinuation due to adverse events in the active-treatment group, but 2.9% in the placebo group—not 3.6%. The analysis covers incretin mimetics, including tirzepatide, rather than GLP-1 receptor agonists alone. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 32 with their cited sources checked
Create a free account to see all 98 claims and to verify the 9 references still open.
- It may state two separate claims as one. 31
- The quote only partly states this claim. 1
- Probably not a substantial claim. 6
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“The first trial reporting detailed results on adjudicated cases of suspected acute pancreatitis was the LEADER trial comparing liraglutide and placebo in patients with T2D (18 cases in 4668 participants randomized to liraglutide treatment vs. 23 in 4672 with placebo treatment) (67).”
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Subcutaneous semaglutide treatment led to an increased number of retinopathy complications in the SUS-TAIN-6 cardiovascular outcomes trial (81).”
Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies
Luppino, F. S., de Wit, L. M., Bouvy, P. F., Stijnen, T., Cuijpers, P., Penninx, B. W. J. H., & Zitman, F. G. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.2 · Cited by 4,322
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“Moreover, in a recent large cardiovascular outcomes trial (SURPASS-CVOT), numerically higher proportions of participants taking tirzepatide (15 mg weekly) reported nausea, vomiting, and diarrhea compared with those taking the selective GLP-1RA dulaglutide (1.5 mg weekly) (25).”
InfluentialNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“This class of drugs is now used widely, with beneficial GLP-1R–mediated effects on body weight and glycemic control, as well as their cardio-renal complications (7, 14).”
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“…studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 2×
“The case reports of pancreatitis prompted searches of adverse event–reporting databases (65), which indicated a substantially higher risk for acute pancreatitis with GLP-1RA treatment.”
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“…studies also indicate that tanycytes, specialized glial cells within the CNS, may facilitate the transportation of peripheral GLP-1RAs, such as semaglutide, into the CNS, bypassing the blood-brain barrier to access appetite-regulating hypothalamic regions such as the arcuate nucleus (60, 61).”
Bjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 1×
“Use of protein supplements has not yet been adequately evaluated in individuals on GLP-1RAs, but there is evidence that an exercise program may increase the proportion of fat mass loss, as opposed to loss of fat-free mass (124).”
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“The Journal of Clinical Investigation The nucleus tractus solitarii projects to multiple regions of the CNS involved in the regulation of appetite, including the hypothalamus, ventral tegmental area, lateral parabrachial nucleus, and nucleus accumbens (58, 59).”
A Patient Questionnaire to Identify Bowel Disease
Talley, N. J., Phillips, S. F., Melton, L. J., Wiltgen, C., & Zinsmeister, A. R. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-8-671 · Cited by 451 · cited 3×
“In the interim, it should be appreciated that several instruments have been used widely in the evaluation of symptoms associated with GI disorders, including the Bowel Disease Questionnaire (BDQ) (29), a comprehensive questionnaire with 71 precisely defined questions.”
Self-citationWei, Y., & Mojsov, S. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01430-9 · Cited by 450 · cited 1×
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
Rentz, A. M., Kahrilas, P., Stanghellini, V., Tack, J., Talley, N. J., De la loge, C., Trudeau, E., Dubois, D., & Revicki, D. A. (2004) · Quality of Life Research · doi:10.1007/s11136-004-9567-x · Cited by 406 · cited 1×
“Abbreviated instruments include the patient assessment of upper GI symptom severity index (PAGI-SYM) (31), the diabetic gastroparesis symptom severity diary (32), the gastroparesis cardinal symptom index (GCSI) (31), and the Nepean Dyspepsia Index (33).”
Self-citationEfficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · cited 1×
“This class of drugs is now used widely, with beneficial GLP-1R–mediated effects on body weight and glycemic control, as well as their cardio-renal complications (7, 14).”
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“More elaborate dose escalation regimens were associated with greater efficacy, GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
Self-citationJohnson, L. N., & Arnold, A. C. (1994) · Journal of Neuro-Ophthalmology · doi:10.1097/00041327-199403000-00011 · Cited by 359
Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01163-7 · Cited by 334
Savage, A. P., Adrian, T. E., Carolan, G., Chatterjee, V. K., & Bloom, S. R. (1987) · Gut · doi:10.1136/gut.28.2.166 · Cited by 334
Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322
GLP-1 Receptor Agonists and the Risk of Thyroid Cancer
Bezin, J., Gouverneur, A., Pénichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J.-L. (2023) · Diabetes Care · doi:10.2337/dc22-1148 · Cited by 320 · cited 2×
“GLP-1RAs versus other glucose-lowering agents (35 cases, hazard ratio [HR] 1.78 [95% CI 1.04–3.05]) ( 78).”
InfluentialSemaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Vilsbøll, T., Bain, S. C., Leiter, L. A., Lingvay, I., Matthews, D., Simó, R., Helmark, I. C., Wijayasinghe, N., & Larsen, M. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13172 · Cited by 318 · cited 2×
“…retinopathy and the induction of rapid reductions in plasma glucose and HbA 1c and found retinopathy complications mainly in those with preproliferative or proliferative retinopathy at baseline who experienced a large reduction in HbA 1c within 16 weeks after initiation of semaglutide (83).”
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318 · cited 1×
“Hathaway et al. reported in a cohort study ( n = 16,827) that there was a higher risk of NAION in individuals prescribed semaglutide (HR 4.28) (89).”
InfluentialAroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290 · cited 1×
“Impor-tantly, there are central pathways that result in a reduction in energy intake without the induction of nausea (62).”
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · cited 1×
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J. (2016) · Diabetes · doi:10.2337/db15-0973 · Cited by 269
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., Ho, A. M.-H., Nersessian, R. S. F., Lima, F. L. M., Silva, M. V., et al. (2023) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2023.111091 · Cited by 259 · cited 1×
“First, it has been observed that individuals on GLP-1RAs undergoing both endoscopy and colonoscopy had a much lower risk of retained gastric contents, suggesting that a prolonged period on a clear liquid diet may reduce this risk (48).”
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Self-citationCardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
Nicholls, S. J., Pavo, I., Bhatt, D. L., Buse, J. B., Del Prato, S., Kahn, S. E., Lincoff, A. M., McGuire, D. K., Miller, D., Nauck, M. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505928 · Cited by 223
Self-citationBorner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Sen, S., Potnuru, P. P., Hernandez, N., Goehl, C., Praestholm, C., Sridhar, S., & Nwokolo, O. O. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.0111 · Cited by 202
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationExpression of the Glucagon‐Like Peptide‐1 Receptor Gene in Rat Brain
Alvarez, E., Roncero, I., Chowen, J. A., Thorens, B., & Blázquez, E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66030920.x · Cited by 194
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“In contrast, in primate and human thyroids, GLP-1R has either not been detected (74) or only found in small fractions of healthy C cells (75), and treatment with liraglutide does not stimulate calcitonin secretion (76).”
Is Weight Loss–Induced Muscle Mass Loss Clinically Relevant?
Conte, C., Hall, K. D., & Klein, S. (2024) · JAMA · doi:10.1001/jama.2024.6586 · Cited by 191 · cited 1×
“The proportion of total weight loss that was fat-free mass was 39% with semaglutide and 25% with tirzepatide (121).”
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Self-citationCastaneda, D., Popov, V. B., Wander, P., & Thompson, C. C. (2019) · Obesity Surgery · doi:10.1007/s11695-018-3493-4 · Cited by 186 · cited 1×
“Furthermore, treatment of T2D and obesity with metabolic surgery, which results in increased GLP-1 secretion (98), has been associated with an increased risk of suicide and self-harm (99), hinting to a potential causal relationship.”
Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y. T., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 180 · cited 1×
“In the vast majority of trials, symptoms are evaluated by participant “self-report” that, while simple, has major limitations (26).”
Self-citationMuller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
Effects of Peptide YY and Neuropeptide Y on Gastric Emptying in Man
Allen, J. M., Fitzpatrick, M. L., Yeats, J. C., Darcy, K., Adrian, T. E., & Bloom, S. R. (1984) · Digestion · doi:10.1159/000199117 · Cited by 170
Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review
Abdeen, G., & le Roux, C. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1945-7 · Cited by 162 · cited 1×
“Furthermore, treatment of T2D and obesity with metabolic surgery, which results in increased GLP-1 secretion (98), has been associated with an increased risk of suicide and self-harm (99), hinting to a potential causal relationship.”
Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160
Self-citationHellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160 · cited 1×
“Indeed, GLP-1R agonism slows gastric emptying (51, 52) and suppresses small intestinal motility (53).”
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157 · cited 3×
“GLP-1R has been detected in healthy thyroid cells other than C cells, as well as in some papillary thyroid cancers (75).”
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157 · cited 1×
“The maximum duration of any of the few studies in which a good technique has been used to quantify emptying (usually scintigraphy) is 16 weeks, and while the magnitude of the delay in emptying at that time point was not as marked as at 5 weeks, it was substantial in some cases (47).”
Self-citationJensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
The Glucagon-Like Peptide-1 Receptor—or Not?
Pyke, C., & Knudsen, L. B. (2013) · Endocrinology · doi:10.1210/en.2012-2124 · Cited by 154 · cited 1×
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146 · cited 1×
“Second, intravenous erythromycin (200 mg), which has been shown to abolish the slowing of gastric emptying by acute intravenous GLP-1 infusion (49), may represent a treatment for individuals identified at having retained gastric content via ultrasonography (50).”
Self-citationKaragiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146 · cited 1×
“In a systematic review, three-component Major Adverse Cardiovascular Events (3-p MACE) was reduced, with an HR of 0.86 (95% CI 0.80–0.92) for those over 65 years old, and there was an even more pronounced effect in those over age 75 (HR 0.75, 95% CI 0.61–0.92) (120).”
InfluentialDo GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145 · cited 1×
“These searches have been reproduced with almost identical results (66), leading to the definition of acute pancreatitis as an “adverse event of special interest” in clinical trials of GLP-1RAs.”
Self-citationGastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144 · cited 1×
“Second, intravenous erythromycin (200 mg), which has been shown to abolish the slowing of gastric emptying by acute intravenous GLP-1 infusion (49), may represent a treatment for individuals identified at having retained gastric content via ultrasonography (50).”
Self-citationKornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143 · cited 1×
“Along those lines, Kornelius et al. reported a three-fold higher risk of major depression, and a doubled risk for anxiety and suicidal behavior in a large ( n = 11,683,623) retrospective study of GLP-1RA users utilizing the TrinetX database (100).”
Calcitonin—a Hormone from the Parathyroid which Lowers the Calcium-level of the Blood
COPP, D. H., & CHENEY, B. (1962) · Nature · doi:10.1038/193381a0 · Cited by 141
Pulmonary aspiration during procedural sedation: a comprehensive systematic review
Green, S. M., Mason, K. P., & KRAUSS, B. S. (2017) · British Journal of Anaesthesia · doi:10.1093/bja/aex004 · Cited by 137 · cited 1×
“However, it should be appreciated that this severe complication is rare and the risk is also less with endoscopy compared with surgical procedures that require general anesthesia (38).”
Sattar, N., Neeland, I. J., Dahlqvist Leinhard, O., Fernández Landó, L., Bray, R., Linge, J., & Rodriguez, A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00027-0 · Cited by 131
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Cai, C. X., Hribar, M., Baxter, S., Goetz, K., Swaminathan, S. S., Flowers, A., Brown, E. N., Toy, B., Xu, B., Chen, J., et al. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.6555 · Cited by 129 · cited 1×
“Cai et al. subsequently confirmed this association in a large multicenter database study of 37.1 million adults, but the incidence was low at 14.5 per 100,000 person-years among semaglutide users, and there was only a modest increase in risk attributable to semaglutide (90).”
InfluentialYeo, Y. H., Gaddam, S., Ng, W. H., Huang, P.-C., Mohamed, G., Samaan, J., Yi-Jin Hsieh, T., Lee, G. Y., Watson, R., Mathur, R., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.03.015 · Cited by 128 · cited 1×
“Population-based studies have reported mixed findings on the potential association between GLP-1RA use and aspiration pneumonia (39– 44).”
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126 · cited 1×
“Given the large and increasing number of currently developed novel agents within the class of GLP-1RAs (127, 128), it can be anticipated that there will be increasing competition to achieve better tolerability and safety. summarized in Table 2.”
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · cited 1×
“After 24 months of follow-up, 68.2% of individuals less than 65 years old had discontinued GLP-1RAs, with the proportion rising to 75.3% for those 65–74 years old and 82.6% for those 75 or older (116).”
InfluentialGlucagon‐like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study
Pasternak, B., Wintzell, V., Hviid, A., Eliasson, B., Gudbjörnsdottir, S., Jonasson, C., Hveem, K., Svanström, H., Melbye, M., & Ueda, P. (2024) · BMJ · doi:10.1136/bmj-2023-078225 · Cited by 125
Cestari, D. M., Gaier, E. D., Bouzika, P., Blachley, T. S., De Lott, L. B., Rizzo, J. F., Wiggs, J. L., Kang, J. H., Pasquale, L. R., & Stein, J. D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.08.017 · Cited by 125 · cited 7×
“Furthermore, some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs (94, 95).”
InfluentialObesity and Eating Disorders in Children and Adolescents: The Bidirectional Link
Stabouli, S., Erdine, S., Suurorg, L., Jankauskienė, A., & Lurbe, E. (2021) · Nutrients · doi:10.3390/nu13124321 · Cited by 123 · cited 1×
“Children and adolescents with obesity are at an increased risk of disordered eating behaviors or eating disorders (107).”
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115 · cited 1×
“Another potential risk of relevance to older individuals is bone loss, which was observed with semaglu-tide (118), although combined treatment with an exercise program may potentially mitigate this risk (119).”
Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
VELLA, A., LEE, J. S., CAMILLERI, M., SZARKA, L. A., BURTON, D. D., ZINSMEISTER, A. R., RIZZA, R. A., & KLEIN, P. D. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00311.x · Cited by 112
Dao, K., Shechtman, S., Weber-Schoendorfer, C., Diav-Citrin, O., Murad, R. H., Berlin, M., Hazan, A., Richardson, J. L., Eleftheriou, G., Rousson, V., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-083550 · Cited by 110 · cited 1×
“In one relatively small study ( n = 168), GLP-1RA use was not associated with an increased risk of pregnancy loss or birth defects in humans (110).”
Chiang, C.-H., Jaroenlapnopparat, A., Colak, S. C., Yu, C.-C., Xanthavanij, N., Wang, T.-H., See, X. Y., Lo, S.-W., Ko, A., Chang, Y.-C., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.06.003 · Cited by 105
Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy
Chou, C.-C., Pan, S.-Y., Sheen, Y.-J., Lin, J.-F., Lin, C.-H., Lin, H.-J., Wang, I.-J., & Weng, C.-H. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.10.030 · Cited by 104
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102 · cited 1×
“Given the large and increasing number of currently developed novel agents within the class of GLP-1RAs (127, 128), it can be anticipated that there will be increasing competition to achieve better tolerability and safety. summarized in Table 2.”
Self-citationMonitoring Suicidal Patients in Primary Care Using Electronic Health Records
Anderson, H. D., Pace, W. D., Brandt, E., Nielsen, R. D., Allen, R. R., Libby, A. M., West, D. R., & Valuck, R. J. (2015) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2015.01.140181 · Cited by 101 · cited 1×
“Furthermore, many of these were pharmacovigilance studies, and the outcome of suicidal ideation was inconsistently documented (104).”
Ismaiel, A., Scarlata, G. G. M., Boitos, I., Leucuta, D.-C., Popa, S.-L., Al Srouji, N., Abenavoli, L., & Dumitrascu, D. L. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01859-6 · Cited by 99 · cited 2×
“In the systematic review of clinical trials mentioned above, tirzepatide conferred the greatest risk of vomiting, RR 13 (15).”
Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., Ghanem, O. M., Levy, S., Joshi, G. P., LaMasters, T., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-024-11263-2 · Cited by 98 · cited 1×
“Multi-society consensus guidelines have, in general, recommended an individualized approach toward the decision to withhold GLP-1RA therapy (46).”
PYY plays a key role in the resolution of diabetes following bariatric surgery in humans
Guida, C., Stephen, S. D., Watson, M., Dempster, N., Larraufie, P., Marjot, T., Cargill, T., Rickers, L., Pavlides, M., Tomlinson, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.040 · Cited by 97
Richard, J. E., Farkas, I., Anesten, F., Anderberg, R. H., Dickson, S. L., Gribble, F. M., Reimann, F., Jansson, J.-O., Liposits, Z., & Skibicka, K. P. (2014) · Endocrinology · doi:10.1210/en.2014-1248 · Cited by 96 · cited 1×
“The Journal of Clinical Investigation The nucleus tractus solitarii projects to multiple regions of the CNS involved in the regulation of appetite, including the hypothalamus, ventral tegmental area, lateral parabrachial nucleus, and nucleus accumbens (58, 59).”
Richards, J., Bang, N., Ratliff, E. L., Paszkowiak, M. A., Khorgami, Z., Khalsa, S. S., & Simmons, W. K. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100080 · Cited by 96
Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2024) · JAMA · doi:10.1001/jama.2024.5003 · Cited by 94
Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13603 · Cited by 93 · cited 1×
“Given the vast number of incretin-based medications under development, mainly aiming at higher efficacy in body weight reduction, one may overlook that adherence to, and persistence of, therapy with GLP-1RAs in real-world studies is relatively low (18, 126).”
Ramracheya, R. D., McCulloch, L. J., Clark, A., Wiggins, D., Johannessen, H., Olsen, M. K., Cai, X., Zhao, C.-M., Chen, D., & Rorsman, P. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.091 · Cited by 92
Glucagon Control on Food Intake and Energy Balance
Al-Massadi, O., Fernø, J., Diéguez, C., Nogueiras, R., & Quiñones, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163905 · Cited by 88
Glucagon‐like peptide‐1 receptor expression in the human eye
Hebsgaard, J. B., Pyke, C., Yildirim, E., Knudsen, L. B., Heegaard, S., & Kvist, P. H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13339 · Cited by 88 · cited 1×
“GLP-1 acts through a class 2 member of the G-coupled protein C receptor family seven-transmembrane receptor (GLP-1R) (8), which is mainly expressed in pancreatic islets, the brain, and the gastrointestinal (GI) tract (9–12), and less prominently in the kidney and eyes (11–13).”
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87 · cited 2×
“Surprisingly, liraglutide treatment elevated serum amylase and lipase activity in the majority of participants (68), but such elevations did not predict clinical acute pancreatitis.”
Self-citationGedulin, B. R., Jodka, C. M., Herrmann, K., & Young, A. A. (2006) · Regulatory Peptides · doi:10.1016/j.regpep.2006.06.004 · Cited by 85
Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node
Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Vega, E. T., Linz, B., Eggertsen, C. H. E., Mulvey, J., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 84
Chen, J.-J., Wu, C.-Y., Jenq, C.-C., Lee, T.-H., Tsai, C.-Y., Tu, H.-T., Huang, Y.-T., Yen, C.-L., Yen, T.-H., Chen, Y.-C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1169 · Cited by 82 · cited 1×
“…cohort study of individuals with T2D and stage 5 chronic kidney disease ( n = 27,279), GLP-1RA use was associated with lower all-cause mortality (HR 0.79; 95% CI 0.63–0.98) and reduced risks of sepsis and infection-related mortality compared with those using dipeptidyl peptidase-4 inhibitors (115).”
InfluentialGrauslund, J., Taha, A. A., Molander, L. D., Kawasaki, R., Möller, S., Højlund, K., & Stokholm, L. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00620-x · Cited by 79 · cited 7×
“Furthermore, some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs (94, 95).”
InfluentialThe Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Abbass, N. J., Nahlawi, R., Shaia, J. K., Allan, K. C., Kaelber, D. C., Talcott, K. E., & Singh, R. P. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.02.025 · Cited by 78 · cited 1×
“Furthermore, some studies have not found any increase in the risk of NAION in individuals using semaglutide or other GLP-1RAs (94, 95).”
Elsaid, M. I., Li, N., Firkins, S. A., Rustgi, V. K., Paskett, E. D., Acharya, C., Reddy, K. R., Chiang, C. W., & Mumtaz, K. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17925 · Cited by 77
Ang, D., Talley, N. J., Simren, M., Janssen, P., Boeckxstaens, G., & Tack, J. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04566.x · Cited by 77 · cited 1×
“In the assessment of treatment outcomes in functional GI disorders such as irritable bowel syndrome (28), the US Food and Drug Administration (FDA) and European Medicine Agency (EMA) have mandated the use of validated questionnaires.”
Self-citationSingh‐Franco, D., Perez, A., & Harrington, C. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 76
Weeda, E. R., Muraoka, A. K., Brock, M. D., & Cannon, J. M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14060 · Cited by 73 · cited 2×
“More elaborate dose escalation regimens were associated with greater efficacy, GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
Glucagon-like Peptide-1 Receptor Agonist Use in Patients With Liver Cirrhosis and Type 2 Diabetes
Yen, F.-S., Hou, M.-C., Cheng-Chung Wei, J., Shih, Y.-H., Hsu, C. Y., Hsu, C.-C., & Hwu, C.-M. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.06.004 · Cited by 73 · cited 2×
“However, another systematic review by Chen et al. (101) found the opposite; GLP-1RA use was associated with a reduction in depression, suggesting that GLP-1RA could potentially be considered an antidepressant therapy.”
Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Crespel, A., De Boisvilliers, F., Gros, L., & Kervran, A. (1996) · Endocrinology · doi:10.1210/endo.137.9.8756532 · Cited by 67 · cited 1×
“The presence of GLP-1R in the rodent thyroid gland and on rodent C cells had been shown earlier (72, 73).”
Castrillon, J., Rele, S., Sumithran, P., Hii, M., Thuraisingam, S., Spelman, T., Phan, T., Choong, P., Dowsey, M., & Shadbolt, C. (2025) · Anaesthesia · doi:10.1111/anae.16601 · Cited by 65
Baumgartner, I., Pacheco‐López, G., Rüttimann, E. B., Arnold, M., Asarian, L., Langhans, W., Geary, N., & Hillebrand, J. J. G. (2010) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2010.01995.x · Cited by 64
Lee, M. M. Y., Sattar, N., Pop-Busui, R., Deanfield, J., Emerson, S. S., Inzucchi, S. E., Mann, J. F. E., Marx, N., Mulvagh, S. L., Poulter, N. R., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0241 · Cited by 63
Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists
Chen, Y.-H., Zink, T., Chen, Y.-W., Nin, D. Z., Talmo, C. T., Hollenbeck, B. L., Grant, A. R., Niu, R., Chang, D. C., & Smith, E. L. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.0081 · Cited by 60
Facciorusso, A., Ramai, D., Dhar, J., Samanta, J., Chandan, S., Gkolfakis, P., Crinò, S. F., Maida, M., Anderloni, A., Boskoski, I., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.021 · Cited by 59 · cited 1×
“Baig et al. (35) and Facciorusso et al. (36) reported an increased risk (odds ratios 4.5 and 5.6, respectively) for premature termination among individuals taking GLP-1RAs, while Singh et al. reported an even greater risk (odds ratio 13.9) (37).”
InfluentialYang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58 · cited 1×
“…by which GLP-1RAs would cause NAION is also unclear, particularly as GLP-1RAs are associated with neuroprotective properties and reductions in ischemic risk (96), but it has been hypothesized to be related, like the exacerbation of retinopathy, to rapid improvements in glycemic control (Figure 3).”
Exenatide-Induced Acute Pancreatitis
Ayoub, W. A., Kumar, A. A., Naguib, H. S., & Taylor, H. C. (2010) · Endocrine Practice · doi:10.4158/ep09104.crr · Cited by 58 · cited 1×
“This contrasts with case reports of acute pancreatitis with the first approved GLP-1RA, exenatide b.i.d. (64).”
Rubino, D., Bjorner, J. B., Rathor, N., Sharma, A. M., von Huth Smith, L., Wharton, S., Wadden, T., Zeuthen, N., & Kolotkin, R. L. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15620 · Cited by 56
Barlowe, T. S., Anderson, C., Sandler, R. S., Subramaniam, D., Muratore, A., Buse, J. B., Gouker, L. N., Majithia, R. T., Shaheen, N. J., Stürmer, T., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.04.038 · Cited by 55
Effects of Glucagon on Myocardial Oxygen Consumption and Coronary Blood Flow in Man and in Dog
Manchester, J. H., Parmley, W. W., Matloff, J. M., Liedtke, A. J., LaRaia, P. J., Herman, M. V., Sonnenblick, E. H., & Gorlin, R. (1970) · Circulation · doi:10.1161/01.cir.41.4.579 · Cited by 54
Baig, M. U., Piazza, A., Lahooti, A., Johnson, K. E., Rangwani, S., Gouda, Z., Mahadev, S., Newberry, C., Hanscom, M., Sampath, K., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.12.019 · Cited by 54
Development and validation of the Diabetes Bowel Symptom Questionnaire
Quan, C., Talley, N. J., Cross, S., Jones, M., Hammer, J., Giles, N., & Horowitz, M. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01553.x · Cited by 52 · cited 1×
“Derived from the BDQ is the Diabetes Bowel Symptom Questionnaire, which also contains items specific for diabetes and its complications (30).”
Self-citationEbrahimi, P., Batlle, J. C., Ayati, A., Maqsood, M. H., Long, C., Tarabanis, C., McGowan, N., Liebers, D. T., Laynor, G., Hosseini, K., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0091 · Cited by 51
Krüger, N., Schneeweiss, S., Desai, R. J., Sreedhara, S. K., Kehoe, A. R., Fuse, K., Hahn, G., Schunkert, H., & Wang, S. V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04102-x · Cited by 48
Coester, B., Pence, S. W., Arrigoni, S., Boyle, C. N., Le Foll, C., & Lutz, T. A. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.11.036 · Cited by 46
Boustani, M. A., Pittman, I., Yu, M., Thieu, V. T., Varnado, O. J., & Juneja, R. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12687 · Cited by 46 · cited 1×
“However, in a study of weekly dulaglutide, there was a comparable incidence of GI adverse effects in those above and below 65 years of age (117).”
Gastrointestinal symptoms in diabetes mellitus, and their relation to anxiety and depression
de Kort, S., Kruimel, J. W., Sels, J. P. J. E., Arts, I. C. W., Schaper, N. C., & Masclee, A. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.01.021 · Cited by 43
Knop, F. K., Urva, S., Rettiganti, M., Benson, C. T., Roell, W. C., Mather, K. J., Haupt, A., & Pratt, E. J. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15875 · Cited by 41 · cited 1×
“In an exploratory clinical trial, a long-acting GIPRA tended to reduce GI adverse events in response to rapidly escalated liraglutide in healthy individuals (23).”
Wilke, T., Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., & Maywald, U. (2016) · Diabetes Therapy · doi:10.1007/s13300-015-0149-4 · Cited by 41 · cited 1×
“More elaborate dose escalation regimens were associated with greater efficacy, GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
Clemens, K. K., Ernst, J., Khan, T., Reichert, S., Khan, M. Q., LaPier, H., Chiu, M., Stranges, S., Sahi, G., Castrillon-Ramirez, F., et al. (2023) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.023 · Cited by 40 · cited 2×
“GI adverse effects are more common in individuals with end-stage renal disease using GLP-1RAs (113), as is hypoglycemia in those using concomitant insulin (114).”
Mochiki, E., Suzuki, H., Takenoshita, S., Nagamachi, Y., Kuwano, H., Mizumoto, A., & Itoh, Z. (1998) · Journal of Gastroenterology · doi:10.1007/s005350050184 · Cited by 38
Joo, J. H., Sharma, N., Shaia, J., Wu, A. K., Skugor, M., Singh, R. P., & Rachitskaya, A. V. (2024) · Ophthalmology Science · doi:10.1016/j.xops.2024.100547 · Cited by 37 · cited 2×
“Some GLP-1Rs are expressed in medullary thyroid cancer (85), but there are almost no GLP-1Rs are in healthy human/ primary C cells (84).”
Zakariassen, H. L., John, L. M., & Lutz, T. A. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13427 · Cited by 37
Singh, S., Rahman, S. H., Khan, N., Rajagopal, A., Shafique, N., Tawde, P., Bhardwaj, V., Suresh Kumar, V. C., Aswath, G., Inamdar, S., et al. (2025) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.10.011 · Cited by 35 · cited 1×
“Baig et al. (35) and Facciorusso et al. (36) reported an increased risk (odds ratios 4.5 and 5.6, respectively) for premature termination among individuals taking GLP-1RAs, while Singh et al. reported an even greater risk (odds ratio 13.9) (37).”
InfluentialTan, T. M. ‐., Minnion, J., Khoo, B., Ball, L., Malviya, R., Day, E., Fiorentino, F., Brindley, C., Bush, J., & Bloom, S. R. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14358 · Cited by 34
Unraveling the Enigma of Nonarteritic Anterior Ischemic Optic Neuropathy
Rizzo, J. F. (2019) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000870 · Cited by 34
Eldor, R., Avraham, N., Rosenberg, O., Shpigelman, M., Golan‐Cohen, A., Cukierman‐Yaffe, T., Merzon, E., & Buch, A. (2025) · Diabetes Care · doi:10.2337/dc25-0690 · Cited by 33 · cited 1×
“It is possible that optimizing dose escalation schedules will improve tolerability, and this should be further explored in future studies (20).”
Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
Kawatani, M., Yamada, Y., & Kawatani, M. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.010 · Cited by 32
Bushi, G., Khatib, M. N., Rohilla, S., Singh, M. P., Uniyal, N., Ballal, S., Bansal, P., Bhopte, K., Gupta, M., Gaidhane, A. M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70037 · Cited by 27 · cited 1×
“…comparable to the results recent systematic reviews and meta-analyses, no link between GLP-1RA use (for obesity and/or T2D) and increased suicidal ideation was identified, but there was substantial heterogeneity between studies, particularly regarding the definition of suicidal ideation (102, 103).”
Foll, C. L., & Lutz, T. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190034 · Cited by 27
Lahoti, S., Catalano, M. F., Geenen, J. E., et al. (1997) · Gastrointestinal Endoscopy · doi:10.1016/s0016-5107(97)70061-0 · Cited by 26
Jones, M. P., Sato, Y. A., & Talley, N. J. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001314 · Cited by 25 · cited 1×
“Abbreviated instruments include the patient assessment of upper GI symptom severity index (PAGI-SYM) (31), the diabetic gastroparesis symptom severity diary (32), the gastroparesis cardinal symptom index (GCSI) (31), and the Nepean Dyspepsia Index (33).”
Self-citationPach, D., Sowa-Staszczak, A., Jabrocka-Hybel, A., Stefańska, A., Tomaszuk, M., Mikołajczak, R., Janota, B., Trofimiuk-Müldner, M., Przybylik-Mazurek, E., & Hubalewska-Dydejczyk, A. (2013) · International Journal of Endocrinology · doi:10.1155/2013/384508 · Cited by 25
Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care · doi:10.2337/dc24-2425 · Cited by 25 · cited 2×
“…trials, 6.5% of those using a GLP-1RA discontinued it due to adverse events versus 3.6% of those on placebo (16), but these rates appear to be higher in observational studies where factors associated with discontinuation were an age of 65 years or older and GI adverse events with treatment (21).”
InfluentialThe efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01337-5 · Cited by 23
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16398 · Cited by 20 · cited 4×
“More elaborate dose escalation regimens were associated with greater efficacy, GI adverse events not infrequently lead to discontinuation of drug treatment, both in randomized clinical trials (16, 17) and in real-world practice (18, 19).”
InfluentialSelf-citationGlucagon and the Cardiovascular System
Williams, J. F. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-71-2-419 · Cited by 20
Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12981 · Cited by 19 · cited 1×
“Subsequent meta-analyses of cardiovascular outcomes trials with GLP-1RAs have clearly excluded a causal role for GLP-1RAs in acute pancreatitis (63, 69, 70), while therapy with inhibitors of dipeptidyl peptidase-4 may lead to a minor elevation of this risk (69).”
Self-citationJalleh, R. J., Jones, K. L., Nauck, M., & Horowitz, M. (2023) · Annals of Internal Medicine · doi:10.7326/m23-2019 · Cited by 18 · cited 1×
“Given the role of GLP-1RAs and other incretin-based medications widely used for the treatment of T2D and obesity, surprisingly little research has been directed at a comprehensive assessment of even the most frequent GI adverse events (125).”
Self-citationNew concepts on acute ocular ischemia
Sharma, R. A., Newman, N. J., & Biousse, V. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000634 · Cited by 16 · cited 1×
“The pathophysiology of this condition is incompletely understood but thought to be related to hypoper-fusion of the optic nerve head leading to edema and infarction of optic nerve fibers (87, 88).”
Foll, C. L., & Lutz, T. A. (2020) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2020.tb00140.x · Cited by 15
Lu, Z., Yeung, C.-K., Lin, G., Yew, D. T. W., Andrews, P. L. R., & Rudd, J. A. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.04.006 · Cited by 13
Al Sakka Amini, R., Ismail, A.-L. S., Al-Aqrabawi, M., Aleyadeh, W., Mohammed, A., Altork, N., Abosheaishaa, H., Elfert, K. A., Goble, S. R., Sawaf, B., et al. (2024) · Cureus · doi:10.7759/cureus.66311 · Cited by 13
Thomas, A. M., Lamb, K., & Howard, O. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.06.003 · Cited by 12 · cited 1×
“GI adverse effects are more common in individuals with end-stage renal disease using GLP-1RAs (113), as is hypoglycemia in those using concomitant insulin (114).”
Fung, K. W., Baye, F., Baik, S. H., & McDonald, C. J. (2025) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2025.2299 · Cited by 12
Huang, X., Wu, M., Huang, B., & Zhang, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1509947 · Cited by 12 · cited 2×
“There was no increased rate of adverse effects leading to discontinuation of treatment in GLP-1RA users compared with non–GLP-1RA users (112).”
InfluentialDevelopment and psychometric evaluation of the Diabetic Gastroparesis Symptom Severity Diary
Fehnel, S. E., Fiedorek, F. T., Nelson, L. M., DiBenedetti, D. B., Spence, S. C., & Carson, R. T. (2019) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s184016 · Cited by 9 · cited 2×
“Abbreviated instruments include the patient assessment of upper GI symptom severity index (PAGI-SYM) (31), the diabetic gastroparesis symptom severity diary (32), the gastroparesis cardinal symptom index (GCSI) (31), and the Nepean Dyspepsia Index (33).”
GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy
Velji-Ibrahim, J., Nathani, P., Patel, H. K., & Sharma, P. (2025) · Endoscopy International Open · doi:10.1055/a-2487-2937 · Cited by 6 · cited 1×
“Population-based studies have reported mixed findings on the potential association between GLP-1RA use and aspiration pneumonia (39– 44).”
Cited by
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 15
“81 Nausea, early satiety, bloating, and mild constipation are common during initiation and dose escalation, likely reflecting delayed gastric emptying.”
Weight Loss Medication Marketing and First Nations People: Disease Awareness or Corporate Profit?
Walker, T., Sherriff, S., & Browne, J. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70246 · Cited by 2
“At the same time, reports of adverse effects and concerns about long-term safety continue to emerge [18].”
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
GLP ‐1 Receptor Agonists for Treating Alcohol Use Disorder: A Critical Review
Woo, S., Zhu, G., Castro, C., Phuong, A., Roy, A., Davis, C. N., & Kranzler, H. R. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70312 · Cited by 3
Metadata
- Authors
- Jalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A.
- Affiliations
- Royal Adelaide Hospital (AU)
- University of Newcastle Australia (AU)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Journal of Clinical Investigation
- Published
- 2026-02-16
- Volume
- 136
- Issue
- 4
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC12904723
- OpenAlex
- W7128962556
- Cited by
- 40
- References
- 152
- Citations by year
- 2026: 40
- FWCI
- 42.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Brown University
- Australian Diabetes Society
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, drug safety, adverse events, type 2 diabetes, obesity, acute pancreatitis, pancreatic cancer, thyroid cancer, retinal complications, gastric emptying, aspiration risk, treatment persistence, pharmacovigilance, risk-benefit assessment, gastrointestinal symptoms
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Gastric Emptying, Humans, Hypoglycemic Agents, Obesity, Pancreatic Neoplasms, Pancreatitis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.